BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the closing of its upsized initial public offering ...

Company also expects to publish third quarter 2025 financial results on the same day pre-market ...

Protext Mobility, Inc. (OTC: TXTM) Announces Launch Phase of Its Next-Generation Investor Relations Suite and Corporate Website Modernization — Ushering in a New Era of Transparency, Innovation, and ...

All Smiles Dental Studio, a leading dental care provider serving North County San Diego, is pleased to announce the expansion of its services by offering comprehensive dental implant solutions, ...

XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add ...

Traditional oxytocin delivery methods—whether injectable or intranasal—require continuous administration due to the hormone's extremely short half-life of just minutes in the bloodstream. Maximus ...

DALLAS, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc. ® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the ...

Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary ...

Cannabix Technologies Inc. (CSE: BLO) (the “Company or Cannabix”) announces a non-brokered private placement for a minimum of 2,127,659 units (the "Units") of the Company at a price of C$0.47 per Unit ...

Third Quarter 2025 Financial Highlights - Cash Position: Cash and cash equivalents were $81.3 million as of September 30, 2025, compared to $90.4 million as of June 30, 2025. - Revenue: ...

REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025. Cash ...

In November 2025, Iovance reported that clinical results for IOV-4001, a PD-1 inactivated TIL cell therapy, in previously treated advanced melanoma patients are anticipated in the first quarter of ...